Clinical Trials Directory

Trials / Unknown

UnknownNCT04939324

Molecular Profiling of Exosomes in Tumor-draining Vein of Early-staged Lung Cancer

Analyse du Profil moléculaire Des Exosomes de la Veine Pulmonaire Dans le Cancer Bronchique de Stade précoce

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
30 (actual)
Sponsor
University Hospital, Limoges · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is an observational prospective single-center study of 30 patients operated for early-staged non-small cell lung cancer. The main aim is the analysis of molecular profiling of exosome with a sample in tumor-draining vein in order to identify prognostic molecular characteristics associated with cancer recurrence after surgery.

Detailed description

Surgical resection remains the best chance for cure in patients with early-stage non-small-cell lung cancer (NSCLC). Unfortunately, approximately 30-50% of patients will relapse within 5-year of curative surgery despite early TNM-stage. The Identification of prognostic biomarkers of relapse is a necessity. Among them, extracellular vesicles (exosomes) study seems promising in early stage cancers and samples directly in tumor-draining vein to. The pulmonary vein is draining blood directly from the lungs and sampling at this location could provide a higher yield for oncosome. The litterature reports that Navarro et al. are the only team to have link exosome characteristics to oncological outcomes following surgery. The investigators propose to analyze the molecular profiling mediated by these extracellular vesicles in the tumor-draining vein of operated patients. A peripheral blood sample is recolted before surgery (D-1 or D0). During oncological lung surgery, the pulmonary tumor-drainage vein is first exposed and punctured with a needle prior to subsequent surgical manipulation for resection (D0). A piece of resected tumor will be analyzed for the study (D0). Quantification and size distribution of exosome and molecular cargo of exosome in blood samples (peripheral and pulmonary vein) and tumor are analyzed (DNA sequencing). Standard clinical and radiological follow-up is then performed and 2-year overall survival and 2-year disease free-survival are checked.

Conditions

Interventions

TypeNameDescription
BIOLOGICALBlood samples at 2 sites: peripheral vein and tumor-draining veinD0: surgery (inclusion): oncological lung resection * Blood samples at 2 sites: peripheral vein and tumor-draining vein * Resected tumor analysis Standard clinical and radiological follow-up during 2 years (medical consultation or phone call)

Timeline

Start date
2021-06-21
Primary completion
2023-08-21
Completion
2024-06-06
First posted
2021-06-25
Last updated
2023-04-10

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04939324. Inclusion in this directory is not an endorsement.